Sandoz Mobile Health Initiative: Empowering Communities Through Accessible Care

By João L. Carapinha

May 5, 2026

Sandoz has launched the Sandoz mobile health initiative in Portugal through its “Sandoz em Marcha” project, sending a mobile health unit to 16 localities over two months to deliver free screenings and health education while strengthening the role of community pharmacies as everyday access points.

Direct Community Screenings Roll Out

The unit provides cardiovascular risk checks plus metabolic, respiratory, venous, digestive, bone and skin assessments with rapid tests, followed by personalized counseling and medical referrals when needed. An accredited pharmacist training program pairs classroom learning with on-site practice, building professional skills while capturing real data on local health needs. These combined services within the Sandoz mobile health initiative target chronic disease burdens, low health literacy and uneven access to care.

Proven Model Expanded from Spain

After successful runs in Madrid and Catalonia, the Portuguese Sandoz mobile health initiative works with pharmacy groups, municipalities, patient associations and media partners to embed the mobile unit in daily community life. The unit functions as both a clinical outpost and an awareness platform, positioning pharmacies as continuous partners in prevention rather than simple dispensaries.

Data Driving Better Access Strategies

Usage figures, detected risk cases and patient feedback from the Sandoz mobile health initiative supply practical inputs for health economics evaluations of community-based prevention. Strengthened pharmacist involvement in early detection and adherence support offers evidence that can shape future reimbursement discussions and highlight how manufacturers can deliver value beyond medicines alone.

Reference url

Recent Posts

FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases

By HEOR Staff Writer

May 7, 2026

Truqap Prostate Cancer Therapy gains key backing from FDA advisors for PTEN-deficient metastatic hormone-sensitive prostate cancer, following strong data from the pivotal trial that demonstrated meaningful delays in disease progression. ODAC Backs Targeted Therapy The ...
EUCOPE Pharmaceutical Regulation: Advocating for Innovative SMEs in a Changing Landscape
EUCOPE pharmaceutical regulation shapes how innovative small and medium-sized enterprises navigate Europe's complex approval pathways. Alexander Natz, Secretary General of EUCOPE, explains how the organi...
Unlocking the Benefits of Cardiovascular Health Checks in EU Prevention Strategies
Cardiovascular health checks deliver strong clinical, economic and societal value when delivered as structured, risk-based programmes connected to ongoing care. This approach supports EU cardiovascular prevention strategies by catching cardiometabolic risks early and reducing long-term events. Th...